Cardiomyopathy in COVID-19 Survivors: Mechanism, Management, and Prevention

  • Renan Sukmawan Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita
Keywords: COVID-19, cardiomyopathy, myocarditis


Coronavirus disease (COVID-19) caused by infection of SARS-CoV-2 as of April 2020 has been confirmed  in more than 2.3 million people, with more than 150 thousands deaths across the globe. It has been known that COVID-19 patients with underlying cardiovascular diseases and its risks including: hypertension, diabetes, coronary artery disease, and cerebrovascular diseases may develop more severe respiratory track symptoms requiring intensive care. Some patients may presenting with myocarditis or acute cardiomyopathy, which has high mortality and morbidity. There was also evidence of myocardial Injury with an increase of troponin in one-third of those infected by covid-19.  It is conceivable that among those who recover from COVID-19 infection, there is a risk of developing further cardiomypathy once the pandemic receding in the future. It is important to pay attention to this survivor group since the pandemic may be lasting for longer period. Optimal medical treatment and comprehensive prevention should be taken to manage those high risk patients of developing cardiomyopathy during hospital care as well post discharge. These includes provide best available COVID-19 drugs, cardiovascular medications, and social preventive measures.


Download data is not yet available.


1. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. 

2. Coronavirus Resource Center, Johns Hopkins University, available at URL
3. Alexander LK, Small JD, Edwards S, Baric RS. An experimental model for dilated cardiomyopathy after rabbit coronavirus infection. J Infect Dis. 1992;166(5):978-85.
4. Taan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease . Int J Cardiol 2020, in press.
5. Schilling JD, Ravichandran AK, Mandras SA. Management of the hospitalized COVID-19 patient with acute cardiomyopathy or heart failure. Cardiology magazine of the American College. Apr 16, 2020.
6. Young BE, Ong SWX, Kalimuddin S, et al., Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore, JAMA (2020) 1–7, Available from: 32125362.
7. Xu JZ,Shi L,Wang Y,etal, Pathological findings ofCOVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med. 2020; 2600 (20): 19–21
8. Hendren NS, Drazner MH, Bozkurt B, MD, Cooper LT. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020; epub ahead of publishing.
9. Akhmerov A, Marban E. COVID-19 and the heart. Circ Res 2020;April 7:[Epub ahead of print]. 

10. Fried JA, Ramasubbu K, Bhatt R, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020:[Epub ahead of print].
11. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020; Epub ahead of print]. 

12. Zhang P, Zhu L, Cai J et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020; URL:
Views & Downloads
Abstract views: 721   
PDF downloads: 457   
How to Cite
Sukmawan, R. (2020). Cardiomyopathy in COVID-19 Survivors: Mechanism, Management, and Prevention. Indonesian Journal of Cardiology, 41(2), 120-4.